Thales Prepares to Secure European Infrastructures Against Attacks From Future Quantum Computers
14.4.2023 15:03:00 EEST | Business Wire | Press release
As a driving force in the second quantum revolution, Thales has joined forces with around twenty deep tech, academic and industry partners, as part of the EuroQCI initiative (European Quantum Communication Infrastructure), which aims to deploy a quantum communication infrastructure for EU member states within three years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230414005211/en/
©Carlos Castilla
By 2040, quantum computers could use their unprecedented computational power to decode encrypted data, incomparably threatening the security of even the best-protected communication systems. EuroQCI aims to counter that threat by developing sovereign systems to protect the communications and data assets of critical infrastructure providers and government institutions.
The longer-term objective of the initiative is to create a Quantum Information Network (QIN) that will harness the phenomenon of quantum entanglement not only to guarantee communications security but also to create networks of quantum sensors and processors, which have the potential to drive exponential increases in the already outstanding performance of quantum sensors and quantum computers.
As part of this effort, today, Thales is breaking new ground as a member of multiple new consortia that have been set up since late 2022 in these domains:
- Quantum repeaters, with the Delft University: QIA (Quantum Internet Alliance) – led by the Delft University of Technology in the Netherlands – is working to demonstrate the feasibility of connecting users in two metropolitan areas 500 km apart, using quantum repeaters, which can compensate for the loss of information via a quantum memory;
- Quantum key distribution: QKISS – coordinated by Exail – and QUARTER – led by LuxQuanta – are developing Quantum Key Distribution systems to protect users' critical communications from cyberattacks.
- Certification of quantum communication: PETRUS – led by Deutsche Telekom – is the official coordinator of 32 EuroQCI projects, on behalf of the European Commission. It is also developing a framework for certification and accreditation of quantum communication products and networks.
- Satellites quantum communications: TeQuantS – led by Thales Alenia Space – aims at developing quantum space-to-Earth communications technologies, necessary for cybersecurity applications and future quantum information networks, through the construction of satellites and optical ground stations by the end of 2026.
Specifically, the Thales teams taking part in these projects are working to develop quantum key generation, distribution and management equipment and the associated communication encryption devices, as well as defining the architecture of these quantum communication infrastructures.
Thales operates the largest quantum physics research facilities in Europe, in partnership with the CNRS, and some 100 engineers and researchers are currently engaged in the development of the quantum solutions (sensors, communications and algorithms) that will play a foundational role in tomorrow's world. These new consortia will all benefit from Thales's multi-disciplinary expertise, in particular in the field of secure communication networks.
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.
Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230414005211/en/
Contact information
PRESS
Thales, Media Relations
Philomène Emptaz
philomene.emptaz@thalesgroup.com
06. 59. 06. 98. 76
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
